Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Zanzalintinib in Combination with Paclitaxel for the Treatment of Recurrent High Grade Uterine Cancer

Trial Status: approved

This phase I/Ib trial studies the side effects and best dose of zanzalintinib in combination with paclitaxel in treating patients with high grade uterine cancer that has come back after a period of improvement (recurrent). Zanzalintinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Giving zanzalintinib in combination with paclitaxel may be safe in treating patients with recurrent high grade uterine cancer.